Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUBT010 biosimilar vs Lucentis in neovascular AMD
NCT04690556Phase 3Completed
- Sponsor
- Lupin Limited
- Start
- Sep 2020
- Primary completion
- May 2024
- Modality
- Antibody Fragments
- Countries
- 7
01
Overview
A Phase 3 trial of LUBT010 in neovascular age-related macular degeneration (NVAMD), sponsored by Lupin Limited. Started Sep 2020; status: completed.
02
Drugs
LUBT010
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04690556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690556.